5 Best S&P 500 Stocks To Buy According to Analysts
In this piece, we will take a look at the five best S&P 500 stocks to buy according to analysts.
Insulet Corp (PODD)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Citadel Investment Group Ken Griffin | 1,331,394 | $288,885,870 | -5% | 0.05% |
| 2. | D1 Capital Partners Daniel Sundheim | 1,004,946 | $218,053,183 | -45% | 3.83% |
| 3. | Slate Path Capital David Greenspan | 444,800 | $96,512,704 | 2.14% | |
| 4. | Rock Springs Capital Management Kris Jenner, Gordon Bussard, Graham Mcphail | 431,750 | $93,681,115 | +14% | 2.3% |
| 5. | Millennium Management Israel Englander | 367,447 | $79,728,650 | +8% | 0.03% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $168.92 | 1 | Officer | 4,032 | 2023-09-19 | Filing | |
| $181.41 | 5,550 | Officer, Director | 34,177 | 2023-08-28 | Filing | |
| $304.75 | 3,300 | Director | 12,221 | 2023-05-23 | Filing | |
| $67.45 | 2,500 | Director | 5,598 | 2017-11-13 | Filing | |
| $58.08 | 2,500 | Officer | 34,709 | 2017-09-06 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $162.92 | 11,609 | Director | 2,567 | 2024-02-28 | Filing | |
| $207.08 | 72 | Director | 2,278 | 2023-12-15 | Filing | |
| $164.33 | 20,000 | Director | 2,567 | 2023-11-13 | Filing | |
| $165.02 | 12,925 | Director | 0 | 2023-11-13 | Filing | |
| $165.02 | 2,075 | Director | 41,130 | 2023-11-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 9,476,623 | $2,056,255,069 | 0.5% | |
| 2. | 8,029,608 | $1,742,264,345 | 0.03% | |
| 3. | 6,102,546 | $1,324,130,516 | 0.03% | |
| 4. | 5,873,891 | $1,274,516,850 | 0.09% | |
| 5. | 3,246,124 | $704,343,984 | 0.13% |
News See All
Here’s Why Insulet (PODD) Detracted in Q4
ClearBridge Investments, an investment management firm, released its fourth-quarter 2023 “ClearBridge Aggressive Growth Strategy” investor letter, which can be downloaded here.
Insulet Corporation (NASDAQ:PODD) Q4 2023 Earnings Call Transcript
Insulet Corporation beats earnings expectations. Reported EPS is $1.44, expectations were $0.67.
25 Most Valuable Medical Device Companies in the US
In this article, we will be taking a look at the 25 most valuable medical device companies in the US.
14 High Growth NASDAQ Stocks That Are Profitable
In this article, we will take a detailed look at the 14 High Growth NASDAQ Stocks That Are Profitable. For a quick overview of such stocks, read our article 5 High Growth NASDAQ Stocks That Are Profitable...
17 High Growth Non-Tech Stocks That Are Profitable
In this article, we will take a detailed look at the 17 High Growth Non-Tech Stocks That Are Profitable. For a quick overview of such stocks, read our article 5 High Growth Non-Tech Stocks That Are...
Insulet Corporation (PODD) Fell on Negative Sentiment Relating to New Weight Loss Medicine
Scout Investments, Inc, an affiliate of Carillon Tower Advisers, Inc, released the “Carillon Scout Mid Cap Fund” third quarter 2023 investor letter. A copy of the same can be downloaded here.
Does Insulet (PODD) Face Challenges from the New Weight Loss Drug?
ClearBridge Investments, an investment management company, released its “ClearBridge Select Strategy” third quarter 2023 investor letter. A copy of the same can be downloaded here.
12 Best Diabetes Stocks To Buy Now
In this article, we shall discuss the 12 best diabetes stocks to buy now.
Billionaire Daniel Sundheim's D1 Capital Portfolio: Top 12 Stock Picks
In this article, we discuss billionaire Daniel Sundheim's D1 Capital portfolio: top 12 stock picks.
Billionaire Hedge Funds
